FALLOPIAN TUBE CANCER

This study tested a new drug called RC88 in 43 women with ovarian, fallopian tube, or peritoneal cancer that stopped responding to platinum chemotherapy. The goal was to see if RC88 could shrink tumors and how safe it was. Participants had already tried at least three other treat…

This study tested a new drug called ZN-c3, alone or with another drug (niraparib), in 117 people with ovarian cancer that stopped responding to platinum-based chemotherapy. The goal was to see if the treatment is safe and can shrink tumors or slow the disease. This is not a cure,…

This study tested a drug called mirvetuximab soravtansine in 79 adults with recurrent ovarian, peritoneal, or fallopian tube cancer that still responds to platinum chemotherapy and has high levels of a protein called folate receptor-alpha. The main goal was to see how many partic…

This early-stage trial tested a new drug called SL-172154 combined with either standard chemotherapy or a targeted therapy in 86 people with ovarian cancer that stopped responding to platinum-based chemo. The main goals were to check safety and find the best dose. Researchers als…

This study tested whether adding two drugs—pembrolizumab (an immunotherapy) and olaparib (a targeted therapy)—to standard chemotherapy could help women with advanced ovarian cancer live longer without their cancer growing. Over 1,300 women with a type of ovarian cancer that does …

This early-stage trial tested a personalized immunotherapy called TG4050 in 64 women with advanced ovarian, fallopian tube, or peritoneal cancer who had completed standard chemotherapy and were in remission. The treatment aims to train the immune system to recognize and attack ca…

This study looked at whether adding the drug aprepitant to the usual two anti-nausea medicines can better prevent nausea and vomiting caused by chemotherapy in people with gynecologic cancers like ovarian, cervical, and endometrial cancer. 143 patients took part. The goal was to …

This study tested a digital tool (a chatbot) to help cancer survivors learn about genetic testing for hereditary cancer risk. 50 adults who had certain cancers (like breast, ovarian, or prostate) took part. The goal was to see if the chatbot was easy to use and if it helped more …

This study looked back at the medical records of 51 people with ovarian, fallopian tube, or peritoneal cancer who took the drug rucaparib. The goal was to see how well the drug works and how safe it is in real-world patients, not just in strict clinical trials. Researchers collec…

This study looked at 1,500 women with advanced ovarian, peritoneal, or fallopian tube cancer to see how genetic changes in their tumors relate to how long they live without the disease getting worse. Researchers collected tumor samples and medical information to build a database …

This study looked at whether it's practical to routinely test tumor tissue from ovarian cancer patients for BRCA gene mutations. Researchers enrolled 200 patients with high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer. The goal was to see if …

This study aimed to create a blood test that could predict when ovarian, peritoneal, or fallopian tube cancer might come back after remission. Researchers looked at proteins in the blood to find a pattern, or 'fingerprint,' linked to relapse. 119 women with stage III or IV cancer…